A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.

Trial Details

NCT ID
NCT06594991
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Fianlimab
  • Cemiplimab
  • Ipilimumab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Stanford, California, United States|37.42411,-122.16608
  • Hartford, Connecticut, United States|41.76371,-72.68509
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • Age ≥ 18 years at the time of informed consent
  • Patient/legal authorized representative (LAR) must be able to provide informed consent.
  • Patient must have a histologically confirmed diagnosis of locally advanced unresectable stage III/IV or metastatic stage IV cutaneous or mucosal me…
  • o For Cohort A, the patient's melanoma must have progressed on prior PD-1 monotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →